HPV Testing Versus Cytology for Cervical Cancer Screening Among Women 50 Years and Older: Evidence From the HPV FOCAL Randomized Controlled Trial Authors: Md Saiful Alam, Laurie W Smith, Lovedeep Gondara, Darrel Cook, Ruth Elwood Martin, Stuart Peacock, Lily Proctor, Gavin Stuart, David Patrick, Eduardo L Franco, Mel Krajden, Anna Gottschlich, Gina S Ogilvie Published: 2026 ABSTRACT ABSTRACTEvidence on the comparative effectiveness of HPV testing versus cytology specifically in women aged ≥ 50 years who are approaching screening cessation remains limited. This analysis included 6471 women aged ≥ 50 at baseline screening in the HPV FOCAL randomized clinical trial. Women were randomly allocated to receive cytology (Control Group, n = 3248, 50.19%) or HPV testing (Intervention Group, n = 3223, 49.81%) at baseline, with co‐testing at 48‐month exit. We calculated incidence rates and risk ratios for CIN2+ detection over follow‐up and compared missed lesions at exit by screening method. At the 48‐month exit, CIN2+ detection was lower among HPV baseline‐negative women than among those in the cytology group (1.61/1000 [95% CI, 0.52–3.76] vs. 3.15/1000 [95% CI, 1.51–5.78]; risk ratio, 0.51 [95% CI, 0.11–0.91]), reflecting higher baseline detection with HPV testing and fewer prevalent lesions at exit. Even with cytology re‐screening at 2 years, 50% of CIN2+ cases were missed compared to 30% with HPV testing. After adjusting for age, education, smoking status, and lifetime sexual partners, the hazard ratio for CIN2+ comparing HPV to cytology was 0.44 (95% CI, 0.22–0.88). Among women aged ≥ 50 years, HPV primary screening was more effective than cytology at detecting CIN2+ lesions and was associated with a continued lower subsequent risk following a negative HPV test, supporting its use in cervical cancer screening programs in this age cohort.Keywords: cervical cancer screening, cervical intraepithelial neoplasia (CIN), human papillomavirus (HPV), randomized controlled trial, women aged 50 and older Abbreviations American Cancer Society Atypical Squamous Cells of Undetermined Significance British Columbia cervical cancer screening confidence interval cervical intraepithelial neoplasia cervical intraepithelial neoplasia grade 2 or worse cervical intraepithelial neoplasia grade 3 or worse Canadian Partnership Against Cancer human immunodeficiency virus human papillomavirus Human Papillomavirus FOr CervicAL Cancer (randomized clinical trial) hazard ratio liquid‐based cytology Low‐grade Squamous Intraepithelial Lesion randomized clinical trial risk ratio United States Preventive Services Task Force World Health Organization Introduction Although cervical cancer is almost entirely preventable, it remains a global public health concern [1]. According to the World Health Organization (WHO), in 2020, an estimated 342,000 women died from cervical cancer [2]. For decades, in many jurisdictions, cervical cancer screening (CCS) with cytology testing (Pap smear) has been considered a public health success, reducing mortality up to 70% [3]. However, cytology has limitations, and screening programs worldwide are transitioning to HPV primary screening because of its higher sensitivity and superior effectiveness in detecting precancerous lesions, so that screening frequency can be reduced [4, 5, 6, 7, 8, 9]. Compared to HPV testing, cytology has substantially lower sensitivity (55.4% vs. 94.6%) despite slightly higher specificity (96.8% vs. 94.1%), resulting in almost half of existing abnormalities being missed [4, 10, 11]. Thus, to compensate for this lower sensitivity, shorter intervals are required between cytology screens [4, 10, 11]. Whereas, given the superior negative predictive value of HPV testing, the interval between negative screens can be safely extended [5, 12, 13, 14, 15]. Because molecular HPV testing has higher sensitivity than cytology, a triage step is required (such as cytology or partial or extended genotyping) to determine which HPV‐positive women are at higher risk for cervical abnormalities requiring further assessment and to reduce unnecessary colposcopy referrals [4, 16, 17]. International and national guidelines, including those from the WHO and the Canadian Partnership Against Cancer, now position HPV‐based screening as one of the central strategies for cervical cancer prevention and elimination [18, 19]. As high‐income countries transition from cytology to HPV primary screening, it is increasingly important to evaluate the effectiveness of HPV testing in women aged ≥ 50 years, who are approaching the end of cervical screening protocols. Currently, the age to exit screening is based on findings from cytology‐based programs, raising questions about whether screening intervals and cessation ages require adjustment in the context of HPV testing [20]. Evidence remains limited regarding age‐specific effectiveness of HPV testing in this older population, despite their unique clinical characteristics. Considerations include a second peak of HPV infections occurring in women aged ≥ 50, and menopausal hormonal changes causing atrophic epithelial changes that may affect test performance [21, 22, 23]. There is a paucity of data regarding the performance of primary HPV testing compared with cytology for detecting precancerous cervical lesions in women aged ≥ 50 years. This study aimed to (1) evaluate the effectiveness of HPV testing compared to cytology in detecting histologically confirmed cervical intraepithelial neoplasia grade 2 or worse (CIN2+ and CIN3+) among women ≥ 50 years; and (2) compare CIN2+ detections missed by primary HPV testing versus cytology. Methods and Materials Design, Settings, and Participants This study is a secondary analysis of the Human Papillomavirus FOr CervicAL Cancer (HPV FOCAL) randomized clinical trial, conducted in British Columbia, Canada, between January 2008 and May 2012 [5]. The HPV FOCAL trial enrolled women aged 25–65 years from Metro Vancouver and Greater Victoria to evaluate the efficacy of primary HPV testing versus cytology testing for CCS. Women were randomly assigned (1:1:1) to three groups: Intervention (HPV testing at 4‐year intervals), Control (cytology testing at 2‐year intervals), or Safety (HPV testing at baseline and cytology at 2 years). Women who were pregnant, had a history of CIN2+ in the last 5 years, had invasive cervical cancer, were HIV positive, or had a history of total hysterectomy were excluded from participation [5]. This is a subgroup analysis restricted to women aged ≥ 50 years who were originally randomized to HPV testing or cytology in the HPV FOCAL trial. Among 6471 HPV FOCAL participants aged ≥ 50 in this analysis, the Control Group (n = 3248) received cytology at baseline and 24 months, while the Intervention Group (n = 3223) received HPV testing at baseline. In the Intervention Group, HPV‐positive women at baseline underwent reflex cytology, and those with abnormal cytology results (≥ Atypical Squamous Cells of Undetermined Significance [ASCUS]) were referred for colposcopy. Control Group participants received reflex HPV testing for ASCUS results, and those ≥ Low‐grade Squamous Intraepithelial Lesion (LSIL) were directly referred for colposcopy [5]. Both groups received cytology and HPV (co‐testing) at 48 months as part of the study exit procedures to maximize the discovery of pre‐cancerous lesions at the end of the study. Those who were positive on either test were referred for colposcopy and biopsy to assess for CIN2+ lesions. Cervical specimens were collected using ThinPrep (Hologic) for liquid‐based cytology (LBC) testing, and HPV testing was performed using the Digene Hybrid Capture 2 High‐Risk HPV DNA (Digene) test. Abnormal cytology results were referred to a cytopathologist for final interpretation. Colposcopy procedures were standardized across all participants, and biopsy results were formally categorized as CIN3+, CIN2+, ≤ CIN1, or normal, with histopathology conducted across two provincial laboratories with no significant difference in outcomes between sites. Figure 1 illustrates the participant flow and screening procedures within the HPV FOCAL trial. Sociodemographic and behavioral characteristics (age, education, lifetime sexual partners, and smoking status) were obtained from the baseline demographic and behavioral questionnaire completed by all FOCAL participants at trial enrollment. The primary outcome of HPV FOCAL was CIN3+, and the secondary outcome was CIN2+. Additional details about the HPV FOCAL trial have been described elsewhere [5]. Study flow diagram showing screening procedures and follow‐up for women aged ≥ 50 years in the HPV FOCAL randomized controlled trial. Statistical Analysis To compare the effectiveness of HPV versus cytology for detecting cervical precancer, sociodemographic and behavioral characteristics (age at baseline, education level, lifetime sexual partners, and smoking status) of participants aged ≥ 50 years were reported as totals and percentages, stratified by study group. Chi‐squared tests assessed between‐group differences. The cumulative incidence of CIN2+ and CIN3+ was calculated for both Intervention and Control Groups across various scenarios. Round 1 encompassed baseline screening and the follow‐up evaluation of baseline screen‐positive participants (12 months) for both groups. The Control Group additionally received a 24‐month cytology screen. The 48‐month exit round included co‐testing results for both groups and incorporated the 24‐month screening results for the Control Group. We calculated cumulative incidence of CIN2+ and CIN3+: (1) at Round 1; (2) at the 48‐month exit; and (3) combined across rounds. Additionally, we calculated the cumulative incidence rate of CIN2+ and CIN3+ among baseline screening‐negative participants. The incidence rate denominator was reported per 1000 women and the Wilson method was utilized to estimate 95% confidence intervals (CIs) [24]. Risk ratios (RRs) and absolute differences (HPV vs. cytology) were also calculated. To visually represent the cumulative incidence of CIN2+, we employed the Kaplan–Meier technique to generate 1 − S(t) actuarial curves. Time to an event was counted from the date of randomization to the date a participant developed histologically confirmed CIN2+ or CIN3+. Participants who did not experience the event were censored either at the time they became ineligible (e.g., due to loss to follow‐up or withdrawal) or, if still eligible and event‐free, at the 48‐month exit screening. Censoring time was defined as the duration from randomization to the censoring date. Cox proportional hazards regression was used to estimate the relative risk of developing CIN2+ or CIN3+ over time, comparing HPV‐based screening to cytology‐based screening. Although participants were randomized at trial entry, restricting our analysis to those aged ≥ 50 years created a subgroup where randomization balance may not hold. Therefore, we adjusted the model for available baseline covariates including age of the participants, education, smoking status, and number of lifetime sexual partners. Age at baseline and educational level were known confounders because they may influence both screening modality effectiveness and disease risk; older age is associated with hormonal changes that can affect cytology accuracy, while education may be associated with underlying factors that influence disease risk [5, 14, 25, 26, 27, 28]. Number of lifetime sexual partners and smoking status were known independent risk factors for cervical precancer, given their established associations with HPV exposure and cervical carcinogenesis [5, 14, 25, 26, 27, 28]. Time to event and censoring were defined as above. Hazard ratios (HRs) and 95% CIs were used to report the association between screening type (cytology vs. HPV) and CIN rates. A p‐value < 0.05 was considered statistically significant. All statistical analyses were performed using R version 4.3.2 [29]. To investigate CIN2+ cases missed by each primary screening method, we conducted a “missed‐case” analysis using HPV and cytology co‐testing performed at the 48‐month study exit. In this analysis, HPV testing was considered the primary test in the Intervention Group and cytology in the Control Group. No triage testing was conducted at the exit co‐test; participants testing positive on either test were referred to colposcopy to maximize ascertainment of CIN2+ at trial end. “Undetected by primary test” was defined as CIN2+ lesions identified at the 48‐month exit that would not have been detected if participants had received only their assigned primary screening test. Accordingly, CIN2+ cases detected by cytology among HPV‐negative women in the Intervention Group and by HPV among cytology‐negative women in the Control Group were classified as missed by the primary test. The proportion of CIN2+ cases undetected by the primary test was calculated and compared between groups. Results Table 1 describes the sociodemographic characteristics of participants, including baseline age, educational level, smoking status, and number of lifetime sexual partners of women ≥ 50 in the intervention and control arm of the HPV FOCAL Trial. There were no statistically significant imbalances in distribution between groups. In both groups, the predominant age category was 50–54 years (42.64% and 42.35%); most participants were non‐smokers (56.86% and 57.88%), had at least some college or university education (76.43% and 75.66%), and reported fewer than five lifetime sexual partners (61.56% and 59.72%). Figure 2 shows the distribution of CIN2+ and CIN3+ detections by screening round and study group. TABLE 1Baseline sociodemographic and lifestyle characteristics of participants aged ≥ 50 in the intervention and control group of the HPV FOCAL trial.Total population, ≥ 50 years: N, 6471CharacteristicsControl (cytology test)Intervention (HPV testing) p 3248 (50.19%)3223 (49.81%)Baseline age of the participants0.9550–54 years1385 (42.64%)1365 (42.35%)55–59 years1079 (33.22%)1083 (33.60%)> 60 years784 (24.14%)775 (24.05%)Ever smoke0.21No1650 (56.86%)1689 (57.88%)Yes1252 (43.14%)1229 (42.12%)Lifetime sex partners0.35< 5 partners1786 (61.56%)1732 (59.72%)6–10 partners601 (20.72%)605 (20.86%)> 10 partners514 (17.72%)563 (19.41%)Education level0.66High school or less688 (23.57%)714 (24.34%)Trade school or college783 (26.82%)736 (25.09%)Some university1448 (49.61%)1483 (50.56%) Note: Percentages were calculated from non‐missing values only. Baseline sociodemographic and lifestyle characteristics of participants aged ≥ 50 in the intervention and control group of the HPV FOCAL trial. Note: Percentages were calculated from non‐missing values only. Flow diagram showing detection of CIN2/CIN3+ in intervention and control groups at different time points among women ≥ 50 years who participated in the HPV FOCAL clinical trial. In the first round, a higher incidence of CIN3+ was observed in the Intervention Group who received HPV testing at baseline, compared to the Control Group. As shown in Table 2, the incidence rate of CIN3+ in the Intervention Group was 1.55 per 1000 (95% CI: 0.50–3.61), contrasting with 0.31 per 1000 (95% CI: 0.01–1.73) in the Control Group, with a RR of 4.99 (95% CI: 0.58–42.72). At 48 months, fewer CIN3+ were detected in the Intervention Group with an incidence rate of 0.93 per 1000 (95% CI: 0.19–2.72) versus 2.79 (95% CI: 1.28–5.30) in the Control Group, with a RR of 0.33 (95% CI: 0.09–1.23). TABLE 2Incidence rate, the absolute difference (HPV‐cytology), and risk ratios (HPV vs. cytology) of CIN2+ and CIN3+ rates among women ≥ 50 years who participated in the HPV FOCAL clinical trial at baseline; at follow‐up (48 months); and at baseline for screening‐negative participants.Age at baseline (≥ 50 years)Intervention group (HPV testing)Control group (cytology testing)Absolute difference (95% CI) (HPV‐cytology)Risk ratio (95% CI) (HPV vs. cytology) p No/totalIncidence rate/1000 (95% CI)No/totalIncidence rate/1000 (95% CI)1st round a CIN3+5/32221.55 (0.50, 3.61)1/32220.31 (0.01, 1.73)1.24 (−0.25, 2.73)4.99 (0.58, 42.72)0.22CIN2+13/32224.02 (2.14, 6.86)6/32221.86 (0.68, 4.04)2.16 (−0.48, 4.80)2.16 (0.82, 5.68)0.11All participants attending the 48‐month screening b CIN3+3/32220.93 (0.19, 2.72)9/32222.79 (1.28, 5.30)−1.86 (−3.97, 0.24)0.33 (0.09, 1.23)0.15CIN2+9/32222.79 (1.27, 5.30)18/32225.59 (3.31, 8.83)−2.79 (−5.95, 0.36)0.50 (0.22, 1.11)0.08At 48 months, among baseline screening negative (cytology or HPV negative) participants c CIN3+1/31030.32 (0.01, 1.79)4/31691.26 (0.20, 2.76)−0.94 (−1.87, 0.62)0.25 (0.04, 3.27)0.38CIN2+5/31031.61 (0.52, 3.76)10/31693.15 (1.51, 5.78)−1.54 (−3.94, 0.87)0.51 (0.11, 0.91)0.01 a Baseline (Round 1) detections by assigned primary screening test: Lesions detected at baseline following primary HPV testing in the HPV arm and primary cytology testing in the cytology arm. b CIN2+ and CIN3+ detected at the 48‐month exit visit using HPV and cytology co‐testing (all participants): Lesions detected at the 48‐month study exit based on HPV and cytology co‐testing in both arms counted irrespective of which test was positive. c CIN2+ and CIN3+ detected at the 48‐month exit among baseline screen‐negative participants: Lesions detected at the 48‐month exit based on HPV and cytology co‐testing among participants who were negative on their assigned primary screening test at baseline. Incidence rate, the absolute difference (HPV‐cytology), and risk ratios (HPV vs. cytology) of CIN2+ and CIN3+ rates among women ≥ 50 years who participated in the HPV FOCAL clinical trial at baseline; at follow‐up (48 months); and at baseline for screening‐negative participants. Baseline (Round 1) detections by assigned primary screening test: Lesions detected at baseline following primary HPV testing in the HPV arm and primary cytology testing in the cytology arm. CIN2+ and CIN3+ detected at the 48‐month exit visit using HPV and cytology co‐testing (all participants): Lesions detected at the 48‐month study exit based on HPV and cytology co‐testing in both arms counted irrespective of which test was positive. CIN2+ and CIN3+ detected at the 48‐month exit among baseline screen‐negative participants: Lesions detected at the 48‐month exit based on HPV and cytology co‐testing among participants who were negative on their assigned primary screening test at baseline. Among baseline screen negative participants, fewer CIN3+ lesions were detected in the Intervention Group (0.32 per 1000; 95% CI: 0.01–1.79) versus the Control Group (1.26 per 1000; 95% CI: 0.20–2.76), with a RR of 0.25 (95% CI: 0.04–3.27) at 48 months. The adjusted HR for CIN3+ in the Intervention Group was 0.39 (95% CI: 0.14–1.12). Similar trends were observed for CIN2+ lesions as shown in Tables 2 and 3. Figure 3 illustrates the cumulative incidence of CIN2+ among baseline screen‐negative participants over 48 months. When both HPV and cytology results at trial exit are considered, cumulative CIN2+ detection was higher in the Control arm than in the Intervention arm, reflecting additional lesions detected with the inclusion of HPV testing at exit among women who had previously been screened with cytology. The figure also presents a hypothetical cytology‐only scenario at trial exit, reflecting the standard screening practice in British Columbia at the time, in which HPV test results at exit are excluded. Under this cytology‐only scenario, among baseline screen‐negative participants, CIN2+ detection in the Control arm was substantially lower, while few to no additional lesions were observed in the Intervention arm. This comparison suggests that HPV testing at exit contributed to the additional CIN2+ detection in the Control arm, whereas few to no lesions remained to be detected at exit in the Intervention arm following earlier detection through HPV‐based screening. TABLE 3Hazard ratio of CIN2+ and CIN3+ for HPV testing compared to cytology testing among women ≥ 50 years who participated in the HPV FOCAL clinical trial.CIN2+CIN3+Unadjusted HR (95% CI)Adjusted HR (95% CI)Unadjusted HR (95% CI)Adjusted HR (95% CI)Different screening strategiesControl (cytology)RefRefIntervention (HPV)0.57 (0.34, 0.93)*0.59 (0.36, 0.98)*0.37 (0.13, 1.04)0.39 (0.14, 1.12) Note: *p < 0.05, **p < 0.01, ***p < 0.001. The model was adjusted for age at baseline, educational level, lifetime sexual partners, and smoking status.Abbreviations: CI, confidence interval; HR, hazard ratio. Hazard ratio of CIN2+ and CIN3+ for HPV testing compared to cytology testing among women ≥ 50 years who participated in the HPV FOCAL clinical trial. Note: *p < 0.05, **p < 0.01, ***p < 0.001. The model was adjusted for age at baseline, educational level, lifetime sexual partners, and smoking status. Abbreviations: CI, confidence interval; HR, hazard ratio. Cumulative incidence of CIN2+ among ≥ 50 baseline screen‐negative (HPV and cytology) participants at 48 months of exit who participated in HPV FOCAL trial. This figure also demonstrates CIN2+ incidence if both groups had received cytology only at the 48‐month study exit. In the missed case analysis, cytology‐negative participants in the Control Group (n = 2824) and HPV‐negative participants in the Intervention Group (n = 2862) at the 48‐month exit were included. In the Control Group, 10 cases of CIN2+ were detected by co‐test at the 48‐month exit; of these, five cases were missed by the cytology test but were detected by the HPV test. In the Intervention Group, nine cases of CIN2+ were detected by co‐test at the 48‐month exit, and the HPV test missed none. Discussion This study evaluated the effectiveness of HPV testing compared to cytology in detecting cervical precancerous lesions (CIN2+ and CIN3+) among women aged ≥ 50 years and compared missed CIN2+ detections between screening modalities at the 48‐month exit. Among women ≥ 50 years, HPV primary screening detected more CIN2+ lesions at baseline than cytology, reflecting HPV testing's enhanced sensitivity for timely identification of prevalent cervical precancer. This earlier detection resulted in superior long‐term protection following a negative HPV test, with lower cumulative incidence at exit among HPV‐negative women compared to cytology‐negative women. Notably, HPV screening at 4‐year intervals missed zero cases at exit co‐testing, whereas cytology‐based screening every 2 years missed half of detected cases. These findings provide age‐specific evidence from a randomized trial confirming that the superior effectiveness of HPV‐based screening observed in broader populations is maintained in women ≥ 50 years, who are approaching the upper age limit for routine screening. The gradual decline in CIN2/3 detection rates with advancing age reflects the natural history of HPV infection, as women who have remained disease‐free through decades of potential exposure represent an inherently lower‐risk group. Nevertheless, given that women aged ≥ 50 are approaching the end of their screening trajectory, even small absolute differences in precancer detection between screening modalities carry meaningful clinical significance, as a missed lesion at this stage has no subsequent routine screen as a safety net. One of the major findings of this study was the superior effectiveness of primary HPV testing compared to cytology for CCS in women ≥ 50 years, which reinforces our understanding of HPV‐based screening performance across different age groups and aligns with prior observational studies. A prospective cohort study conducted among 4043 women ≥ 50 years who participated in an organized screening program in Denmark, comparing the diagnostic accuracy of primary HPV and cytology test, with or without opposite triage test, found primary HPV testing had the highest sensitivity, with the addition of cytology triage significantly enhancing specificity [30]. The Kaiser Permanente Northern California cohort study involving nearly 1 million women aged ≥ 50 found that the performance of one negative HPV test was comparable to that of a negative co‐test in predicting low CIN3+ risk [31]. However, that study used co‐testing at 3‐year intervals and did not examine HPV testing alone or compare directly with cytology‐based screening. Importantly, our study is the first analysis leveraging data from a large, randomized trial to directly compare HPV primary screening (at 4‐year intervals) versus cytology screening (at 2‐year intervals) specifically in women ≥ 50 years. Our findings demonstrate that adding cytology to HPV testing at 4‐year intervals detected zero additional CIN2+ cases, suggesting limited added value of co‐testing in this age group when longer screening intervals are employed with HPV testing. Among women who tested negative at baseline, the cumulative incidence of developing CIN2+ among those with a negative HPV test was half that of those with a negative cytology screen. This finding reinforces the safety and rationale for the established 5‐year screening interval with HPV testing, demonstrating that this interval remains appropriate specifically for women aged 50 and older. Similar to our findings, a modeling study utilizing a Markov model found that women with a negative HPV test at age 55 experienced a significantly lower lifetime risk of cervical cancer than those with negative cytology [32]. Even after adjusting for established cervical cancer risk factors (age, education, smoking status, and lifetime sexual partners), the HR for CIN2+ detection comparing HPV to cytology testing remained significant, indicating that HPV testing performs more consistently as a screening method independent of individual risk factors. Although participants were originally randomized in the HPV FOCAL trial, restricting our analysis to the subgroup of women ≥ 50 years meant that randomization balance might not be maintained within this age stratum. We therefore adjusted for these baseline covariates to account for potential confounding and isolate the independent effect of screening modality. The persistence of a significant protective effect of HPV testing after these adjustments strengthens confidence in its superiority for this age group. These findings demonstrate that primary HPV screening enhances early detection and long‐term prevention of cervical cancer in older women. Similar findings were observed in several large‐scale clinical trials; however, those studies did not provide age‐specific analysis for women ≥ 50 years [4, 5, 8, 33]. Our study provides direct evidence confirming that the superior protective effect of HPV testing observed in screening populations across all eligible ages extends to women ≥ 50 years, who were previously not evaluated separately in randomized trials. The missed case analysis further underscores the superiority of HPV testing over cytology. Cytology screening with two rounds of screening resulted in more missed CIN2+ cases compared to HPV screening every 48 months among women ≥ 50 years. Our findings align with the HPV FOCAL trial participants across all ages, which found that cytology missed over eight times more precancers than HPV screening at extended intervals (40.3% vs. 6.1% of detected CIN2+ cases) [15]. This consistency across age groups, including women ≥ 50 years, reinforces the robustness of HPV testing's superior performance. This suggests that HPV testing not only had a higher detection rate but also reduced the likelihood of missed cases, demonstrating there may be limited potential benefit of the addition of cytology (co‐testing). Primary HPV screening, compared to co‐testing, may reduce unnecessary follow‐up procedures, associated costs, and burden on healthcare systems. Strength and Limitations This study utilizes high‐quality data from the HPV FOCAL randomized clinical trial, which includes blinded histopathological exams and centralized laboratory testing. Further, it focuses on an age group that has been underrepresented in previous studies. Different governing bodies, including the United States Preventive Services Task Force (USPSTF), WHO, and American Cancer Society (ACS), have primarily relied on study findings and mathematical modeling to identify the appropriate upper age to stop screening [16, 17, 34]. There had been a lack of evidence regarding how the HPV test would perform as a primary CCS approach for women ≥ 50 years, who had unique characteristics and were close to exiting CCS [35]. This study provides evidence supporting the superior performance of HPV testing over cytology in detecting precancerous cervical lesions, specifically among women ≥ 50 years. While this analysis provided valuable insights, several limitations should be acknowledged. A key limitation of this analysis is the relatively small number of CIN2+ and CIN3+ events observed in the ≥ 50 age group, which reflects the naturally lower burden of high‐grade cervical lesions in this population. This resulted in wide CIs around several estimates, and a number of findings, particularly for CIN3+, did not reach statistical significance. Findings should therefore be interpreted with appropriate caution. Nevertheless, the consistent direction of effect across all analyses, combined with the statistically significant findings for CIN2+ among baseline screen‐negative participants, supports the overall conclusions regarding the superior performance of HPV testing in this age group. Consented participants in the HPV FOCAL trial were well‐screened and highly educated. As a result, their cervical cancer risk profiles may differ from those of under‐screened, higher‐risk populations, and the findings may not be fully generalizable to these groups. However, the majority of those participating in average risk screening are routinely engaged, and these findings are directly generalizable to women in the BC population‐based screening setting and to a large portion of those in similar organized screening programs. Future Directions and Conclusion As national and global CCS programs shift toward HPV primary screening, timely population‐based evidence is needed to support policy and guideline development. Our results show that among women ≥ 50 years, who, although, are nearing the end of the screening trajectory, remain engaged in screening. HPV testing provides greater reassurance against future detection of precancerous cervical lesions than cytology, reinforcing its role as the preferred screening modality in this age group and aligning with WHO and CPAC elimination strategies. Looking ahead, research should focus on identifying the long‐term risk of CIN3+ following a negative HPV test to establish optimal screening intervals for older women. Evaluating colposcopy referral patterns in this population will also help assess the resource implications of transitioning to HPV‐based screening. In addition, future work could examine whether the upper age at which CCS ceases can be safely lowered when HPV testing is used as the primary approach. Author Contributions Md Saiful Alam: formal analysis, visualization, writing – original draft, writing – review and editing, software. Laurie W. Smith: conceptualization, funding acquisition, methodology, supervision, project administration, resources. Lovedeep Gondara: formal analysis, writing – review and editing, data curation. Darrel Cook: methodology, writing – review and editing. Ruth Elwood Martin: conceptualization, funding acquisition, writing – review and editing. Stuart Peacock: conceptualization, funding acquisition, writing – review and editing, methodology. Lily Proctor: writing – review and editing, conceptualization, funding acquisition, methodology. Gavin Stuart: conceptualization, writing – review and editing, methodology, supervision. David Patrick: conceptualization, methodology, writing – review and editing, supervision. Eduardo L. Franco: conceptualization, writing – review and editing, funding acquisition. Mel Krajden: writing – review and editing, conceptualization, funding acquisition. Anna Gottschlich: supervision, conceptualization, methodology, writing – review and editing, formal analysis. Gina S. Ogilvie: conceptualization, methodology, funding acquisition, writing – review and editing, formal analysis, visualization. Funding This work is based on data from the HPV FOCAL randomized trial and FOCAL DECADE follow‐up study, which were supported by the Canadian Institutes of Health Research (CIHR; MCT82072) and the National Institutes of Health (NIH; R01 CA221918), respectively. Additional postdoctoral research support was provided by Michael Smith Health Research BC (RT‐2021‐1595). Ethics Statement This study is a secondary analysis of data from the HPV FOCAL randomized clinical trial. Participants in the parent trial provided written informed consent at enrollment. Ethics approval for the HPV FOCAL trial (H06‐04032) and its extended follow‐up (FOCAL‐DECADE; H18‐02063) was granted by the University of British Columbia Clinical Research Ethics Board. The present secondary analysis was conducted in accordance with these approvals. Conflicts of Interest E.L.F. discloses that his university has received unconditional funding from Merck in partial support for research projects he initiated; he has also received consultancy fees from Merck; and he is a co‐owner of a patent on methylation markers in cervical cancer screening. These disclosures are unrelated to the topic of the present paper. The other authors declare no conflicts of interest. Alam M. S., Smith L. W., Gondara L., et al., “ HPV Testing Versus Cytology for Cervical Cancer Screening Among Women 50 Years and Older: Evidence From the HPV FOCAL Randomized Controlled Trial,” International Journal of Cancer 159, no. 8 (2026): 2066–2074, 10.1002/ijc.70616. Previous Presentation: Portions of this work were previously presented at the following conferences: (1) EUROGIN International Multidisciplinary HPV Congress 2024, Stockholm, Sweden, March 16, 2024 (Oral). (2) Ninth Annual Women's Health Research Symposium, University of British Columbia, Vancouver, Canada, March 8, 2024 (Poster). (3) Canadian Cancer Research Conference, Halifax, Canada, November 12–14, 2023 (Oral and Poster). (4) Women's Health Research Conference, Partnership for Women's Health Research Canada, University of British Columbia, Vancouver, Canada, June 14, 2023 (Oral and Poster). (5) 35th International Papillomavirus Conference (IPVC 2023), Seattle, USA, April 22, 2023 (Poster). (6) Healthy Starts, BC Children's Hospital Research Institute, Vancouver, Canada, February 1, 2023 (Poster). (7) BC Cancer Summit‐TFRI BC Node Research Day, Vancouver, Canada, November 24–26, 2022. Data Availability Statement De‐identified data that support the findings of this study are available from the corresponding author upon reasonable request. References Associated Data Data Availability Statement De‐identified data that support the findings of this study are available from the corresponding author upon reasonable request.